Please ensure Javascript is enabled for purposes of website accessibility

Why Agenus Inc. Stock Briefly Popped Today

By George Budwell – Oct 23, 2017 at 12:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After the market had time to reflect on Agenus' new CAR-T venture, investors were unimpressed by its prospects.

What happened

Agenus (AGEN -2.22%), a clinical-stage cancer immunotherapy company, saw its shares open up 13% higher Monday on trading volumes nearly six times the daily average. The move came in response to its launch of a new immuno-oncology subsidiary called AgenTus Therapeutics, Inc.

The biotech's new venture will focus on the development of adoptive cell therapies, such as chimeric antigen T cell receptor therapies (CAR-T), and T cell receptors (TCRs) designed to treat both solid tumors and various types of blood cancers. Despite that brief double-digit spike, however, Agenus' stock almost immediately began to cool off, fell into the red for a few minutes late in the morning, and as of noon EDT, was trading up by only around 2%.

A 3-D rendering of cancer cells.

Image Source: Getty Images.

So what

Adoptive cell therapies have been in the spotlight over the past few weeks because of Gilead Sciences' $12 billion buyout of Kite Pharma -- along with the back-to-back regulatory approvals of Gilead/Kite's CAR-T therapy Yescarta and Novartis' Kymriah. Genetically modified cell therapies have rapidly come of age as potent anti-cancer treatments, and Agenus apparently wants to get in on the action. 

Now what

While adoptive cell therapies are now a validated anti-cancer platform, Agenus is probably way too late to this particular party to derive much of a benefit. Gilead and Novartis already have the first-mover advantage, after all, and a slew of other companies such as Bellicum Pharmaceuticals, bluebird bio., Celgene, Juno Therapeutics, and ZioPharm Oncology -- to name just a few -- are also racing to bring their own cell-based cancer therapies to market within the next few years.

The bottom line is that Agenus' adoptive cell-based therapy venture doesn't seem to have much a chance in light of the prevailing market conditions, which is probably why its 13% spike Monday didn't last long.   

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio, Celgene, and Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy.

Stocks Mentioned

Agenus Stock Quote
$2.64 (-2.22%) $0.06
Celgene Stock Quote
Gilead Sciences Stock Quote
Gilead Sciences
$87.90 (0.08%) $0.07
Bluebird Bio Stock Quote
Bluebird Bio
$7.61 (-2.31%) $0.18
Alaunos Therapeutics, Inc. Stock Quote
Alaunos Therapeutics, Inc.
$0.64 (-0.20%) $0.00
Juno Therapeutics Inc. Stock Quote
Juno Therapeutics Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.